<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02805010</url>
  </required_header>
  <id_info>
    <org_study_id>SIM-126-I</org_study_id>
    <nct_id>NCT02805010</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single Dose of Abatacept 125mg Administered Subcutaneously in Chinese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the single dose PK, safety, tolerability and&#xD;
      immunogenicity of abatacept 125mg administered SC in Chinese healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Day1 to Day71</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>Day1 to Day71</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life period (T1/2)</measure>
    <time_frame>Day1 to Day71</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to peak (Tmax)</measure>
    <time_frame>Day1 to Day71</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event (AE)</measure>
    <time_frame>Signed Informed consent form (ICF) to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-abatacept antibodies</measure>
    <time_frame>Day1 to Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti cytotoxic T lymphocyte-associated antigen-4(CTLA-4) antibodies</measure>
    <time_frame>Day1 to Day 71</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Rheumatoid Arthritis (RA)</condition>
  <arm_group>
    <arm_group_label>Subcutaneous(SC) Abatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>On Day 1, subjects will receive a single SC dose of abatacept 125mg</description>
    <arm_group_label>Subcutaneous(SC) Abatacept</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>On Day 1, subjects will receive a single SC dose of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects are willing to participate in this study and signed informed consent;&#xD;
&#xD;
          -  Healthy subjects, as determined by no clinically significant deviation from normal in&#xD;
             medical history, physical examination, Electrocardiograph（ECG）, and clinical&#xD;
             laboratory determinations;&#xD;
&#xD;
          -  Body weight for male must be≥50 kg, for female be≥45 kg, and all subjects must be&#xD;
             ≤100kg;&#xD;
&#xD;
          -  Body mass index (BMI) is 19-26 kg/m2 (boundary value included), [BMI = body weight&#xD;
             (kg) / height (m)2];&#xD;
&#xD;
          -  Men and women, 18-45 years old (boundary value included);&#xD;
&#xD;
          -  Women of child bearing potential (WOCBP) must be using the adequate method of&#xD;
             contraception to avoid pregnancy throughout the study, for 4 weeks before and for up&#xD;
             to 10 weeks after administration of abatacept, male subjects of childbearing potential&#xD;
             must be using an adequate method of contraception throughout the study and for up to&#xD;
             10 weeks after administration of investigational product in such a manner that risk of&#xD;
             pregnancy is minimized;&#xD;
&#xD;
               -  WOCBP include any female who has experienced menarche and who has not undergone&#xD;
                  successful surgical sterilization (hysterectomy, bilateral tubal ligation or&#xD;
                  bilateral oophorectomy) or is not postmenopausal. Post-menopausal is defined as:&#xD;
                  Amenorrhea ≥ 12 consecutive months without another cause, or for women with&#xD;
                  irregular menstrual periods and on hormone replacement therapy (HRT), a&#xD;
                  documented serum follicle stimulating hormone (FSH) level &gt; 35 mIU/mL;&#xD;
&#xD;
               -  Women who are using oral, implanted or injectable contraceptive hormones or&#xD;
                  mechanical products such as an intrauterine device or barrier methods (diaphragm,&#xD;
                  condoms, spermicides) to prevent pregnancy or practicing abstinence or where&#xD;
                  partner is sterile (e.g., vasectomy), should be considered to be of child bearing&#xD;
                  potential;&#xD;
&#xD;
          -  WOCBP must have a negative serum pregnancy test within 24 hours prior to study&#xD;
             medication administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  WOCBP and males subjects of childbearing potential who are unwilling or unable to use&#xD;
             an acceptable method to avoid pregnancy for up to 10 weeks after administration of the&#xD;
             study medication;&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding;&#xD;
&#xD;
          -  History or concurrent diseases of central nervous system, cardiovascular system,&#xD;
             renal, hepatic, digestive tract, respiratory system, metabolism and musculoskeletal&#xD;
             system. (including but not limited to arrhythmia, bradycardia, hypotension, coronary&#xD;
             heart disease, bronchial asthma, diabetes, hyperthyroidism, Parkinson's disease,&#xD;
             epilepsy, shaking palsy, cancer, etc.). Or any other diseases or physiological&#xD;
             abnormalities, which might affect study results;&#xD;
&#xD;
          -  Any major surgery within 4 weeks of enrollment;&#xD;
&#xD;
          -  Splenectomized subjects;&#xD;
&#xD;
          -  Exposed to any investigational medication within 3 months of enrollment, or plan to&#xD;
             receive other investigational medication during the study;&#xD;
&#xD;
          -  Donation of blood or plasma within 3 months of enrollment, or plan to donate blood or&#xD;
             plasma during the study or within one month after the end of the study;&#xD;
&#xD;
          -  Blood transfusion within 4 weeks prior to enrollment;&#xD;
&#xD;
          -  Subjects who is a current smoker (defined as individuals who smoked for more than 6&#xD;
             months, and smoked for ≥ 5 cigarettes per day before screening), ≥ 3 cups of coffee or&#xD;
             other coffee drinks or ≥ 5 cups of tea per day;&#xD;
&#xD;
          -  Subjects who have a history of drug or alcohol abuse;&#xD;
&#xD;
          -  Subjects with tuberculosis (TB) risk, specially:&#xD;
&#xD;
               -  Having clinical, imaging or lab test evidences of current active or latent&#xD;
                  pulmonary tuberculosis;&#xD;
&#xD;
               -  Having active pulmonary tuberculosis during the past 3 years, even if had been&#xD;
                  treated;&#xD;
&#xD;
               -  Having history of active pulmonary tuberculosis more than 3 years ago, unless the&#xD;
                  appropriate duration and types of anti-tuberculosis drug is well documented.&#xD;
&#xD;
          -  Subjects with herpes zoster that resolved less than 2 months prior to enrollment;&#xD;
&#xD;
          -  Subjects who had any acute or chronic bacterial infection in the previous 3 months&#xD;
             prior to enrollment;&#xD;
&#xD;
          -  Subjects who have acute and latent bacterial and viral infection (as assessed by the&#xD;
             investigator) at the time of enrollment, including subjects with evidence of Human&#xD;
             Immunodeficiency Virus (HIV) infection;&#xD;
&#xD;
          -  Subjects who have mental or physical disability;&#xD;
&#xD;
          -  Subjects who have any surgical and medical conditions, which might be harmful if&#xD;
             subjects participate in the study, or which might change the absorption, distribution,&#xD;
             metabolism and excretion of investigational medication;&#xD;
&#xD;
          -  Heart beat rate &lt;50 beats /min or &gt;100 beats /min (heart rates should be measured&#xD;
             after a brief period of rest, at least 5 minutes.), systolic blood pressure &gt;140 mmHg&#xD;
             or diastolic blood pressure &gt;90 mmHg, body temperature (forehead)&gt;37.6℃;&#xD;
&#xD;
          -  Hgb &lt; LLN (lower limit of normal), the absolute neutrophil count (ANC) &lt;1.5×10^9/L,&#xD;
             platelets &lt;100×10^9/L; bilirubin &gt; ULN (upper limit of normal), serum creatinine &gt; ULN&#xD;
             ; glutamic oxaloacetic transaminase (AST) &gt; ULN, glutamic pyruvic transaminase (ALT) &gt;&#xD;
             ULN;&#xD;
&#xD;
          -  Subject who have active infection, or positive for hepatitis-B surface antigen&#xD;
             (HBs-Ag), hepatitis-C antibody (HCV-Ab), or HIV-Ab;&#xD;
&#xD;
          -  Positive urinalysis for protein, or other abnormal urinalysis tests which were judged&#xD;
             to have clinical significance by investigators;&#xD;
&#xD;
          -  History of drug allergy, postural hypotension, or idiopathic allergy;&#xD;
&#xD;
          -  Prior exposure to abatacept (CTLA4-Ig), belatacept (LEA29Y) or any leukocyte depleting&#xD;
             agent;&#xD;
&#xD;
          -  Use of any prescription drugs within 4 weeks (or 5 half-lives, whichever is longer)&#xD;
             prior to enrollment, Use of any OTC medications and herbal preparations within 1 week&#xD;
             prior to enrollment, unless the medical monitoring shows that the drug has been&#xD;
             cleared;&#xD;
&#xD;
          -  Vaccination with any live vaccine within 4 weeks prior to study medication&#xD;
             administration on Day 1;&#xD;
&#xD;
          -  Administration of oral polio vaccine to subject or house hold contacts during the&#xD;
             course of study;&#xD;
&#xD;
          -  Prisoners or subjects who are involuntarily incarcerated;&#xD;
&#xD;
          -  Subjects who are compulsorily detained for treatment either a psychiatric or physical&#xD;
             (e.g., infectious disease) illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>June 12, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>December 3, 2016</last_update_submitted>
  <last_update_submitted_qc>December 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

